Changes to This Summary (05/23/2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added text to state that nilotinib-treated patients had a lower rate of treatment-emergent BCR/ABL mutations than did imatinib-treated patients (cited Hochhaus et al. as reference 8).
Added text to state that a single-center, retrospective analysis of 483 patients with chronic phase CML who were treated with imatinib, dasatinib, or nilotinib indicated that patients who have better than 35% t(9;22)+ cells at 3 months of therapy have inferior event-free, transformation-free, and overall survival rates compared with patients who have better early cytogenetic responses (cited Jain et al. as reference 23).
Added Tyrosine kinase inhibitor-resistant CML as a new subsection.
Added Jain et al. as reference 4.
Added text to state that for patients resistant to the tyrosine kinase inhibitors, omacetaxine mepesuccinate has shown a hematologic response rate of 67% and a median progression-free survival of 7 months in a small, phase II study of 46 patients (cited Cortes et al. as reference 21 and level of evidence 3iiiDiv).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.